Marwin Li, Natalie M Perlov, Jena Patel, Dev Amin, Ayan Kumar, Zachary D Urdang, Thomas O Willcox, Rebecca C Chiffer
{"title":"Association of type 2 diabetes mellitus with sensorineural hearing loss - A population-based analysis.","authors":"Marwin Li, Natalie M Perlov, Jena Patel, Dev Amin, Ayan Kumar, Zachary D Urdang, Thomas O Willcox, Rebecca C Chiffer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To test the hypothesis that patients with poorly controlled type 2 diabetes mellitus are more likely to develop sensorineural hearing loss (SNHL) than non-diabetic patients.</p><p><strong>Study design: </strong>Retrospective cohort study.</p><p><strong>Setting: </strong>TriNetX US Collaborative Network (2003-2022).</p><p><strong>Methods: </strong>Electronic medical record data from the TriNetX US Collaborative Network was queried for subjects without prior hearing loss, defined using medical billing codes (ICD-10, CPT, etc.), who were diagnosed with type 2 diabetes mellitus after January 2003. Patients were stratified by most recent HbA1c (8.0-13.9% or ≥14.0%) and by age at diagnosis (21-30, 31-40, 41-50, 51-60, 61-70, ≥71 years). Primary outcome was development of SNHL ≤20 years after diabetes diagnosis. Cohorts were propensity-score matched for age, gender, race, and hearing loss-related conditions, including vascular disease and tobacco/nicotine use. Hearing loss risk in each cohort were compared against age-matched non-diabetic subjects.</p><p><strong>Results: </strong>All diabetic patients had greater risk of SNHL compared to age-matched controls; having a higher HbA1c (≥14.0%) additionally associated with greater risk than a lower HbA1c (8.0-13.9%) for all age groups except 21-30 and 31-40 years. Furthermore, risk was higher for older patients of both HbA1c ranges, with patients ≥71 years at diagnosis having greatest risk. Patients ≥71 with HbA1c ≥14.0% (n = 3,870) had a 0.51% (95% confidence interval: 0.28-0.74, p < 0.0001) greater hearing loss risk, and patients with HbA1c 8.0-13.9% (n = 155,066) had 0.24% (0.22-0.27, p < 0.0001) greater risk.</p><p><strong>Conclusion: </strong>Type 2 diabetes diagnosis appears to strongly associate with greater risk of developing SNHL, especially in older patients. Audiometric screening may be warranted.</p>","PeriodicalId":94154,"journal":{"name":"Neuro endocrinology letters","volume":"45 5","pages":"341-351"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro endocrinology letters","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To test the hypothesis that patients with poorly controlled type 2 diabetes mellitus are more likely to develop sensorineural hearing loss (SNHL) than non-diabetic patients.
Study design: Retrospective cohort study.
Setting: TriNetX US Collaborative Network (2003-2022).
Methods: Electronic medical record data from the TriNetX US Collaborative Network was queried for subjects without prior hearing loss, defined using medical billing codes (ICD-10, CPT, etc.), who were diagnosed with type 2 diabetes mellitus after January 2003. Patients were stratified by most recent HbA1c (8.0-13.9% or ≥14.0%) and by age at diagnosis (21-30, 31-40, 41-50, 51-60, 61-70, ≥71 years). Primary outcome was development of SNHL ≤20 years after diabetes diagnosis. Cohorts were propensity-score matched for age, gender, race, and hearing loss-related conditions, including vascular disease and tobacco/nicotine use. Hearing loss risk in each cohort were compared against age-matched non-diabetic subjects.
Results: All diabetic patients had greater risk of SNHL compared to age-matched controls; having a higher HbA1c (≥14.0%) additionally associated with greater risk than a lower HbA1c (8.0-13.9%) for all age groups except 21-30 and 31-40 years. Furthermore, risk was higher for older patients of both HbA1c ranges, with patients ≥71 years at diagnosis having greatest risk. Patients ≥71 with HbA1c ≥14.0% (n = 3,870) had a 0.51% (95% confidence interval: 0.28-0.74, p < 0.0001) greater hearing loss risk, and patients with HbA1c 8.0-13.9% (n = 155,066) had 0.24% (0.22-0.27, p < 0.0001) greater risk.
Conclusion: Type 2 diabetes diagnosis appears to strongly associate with greater risk of developing SNHL, especially in older patients. Audiometric screening may be warranted.